Filing Flows › RenovoRx (RNXT) › Q2 2025
RenovoRx (RNXT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
RenovoRx (RNXT) reported revenue of $422K for the second quarter 2025 (Q2 2025) and +114% from the quarter before. Operating margin was -634.6%, net loss $2.9M (686.0% of revenue).
RenovoRx, Q2 2025: revenue $422K, operating margin -634.6%, net loss $2.9M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $422K | +114% | — |
| Operating profit | −$2.7M | — | — |
| Net earnings | −$2.9M | — | — |
| Operating cash flow | −$2.3M | — | — |
What changed
Revenue was $422K in Q2 2025, up 114% from the previous quarter.
Gross margin was 64.0%. Operating costs exceeded revenue by $2.7M, an operating margin of -634.6%. The quarter ended with a net loss of $2.9M, wider than the previous quarter's $2.4M loss.
Operating cash flow was −$2.3M. Non-cash charges added back $1.0M of depreciation and amortization and $345K of share-based compensation. Working capital and other items used $752K.
Questions
What was RenovoRx's revenue in the second quarter 2025?
RenovoRx (RNXT) reported revenue of $422K for the second quarter 2025 (Q2 2025) and +114% from the quarter before.
Was RenovoRx profitable in the second quarter 2025?
Operating loss was $2.7M (-634.6% of revenue) and net loss $2.9M.
Source: RenovoRx 10-Q on SEC EDGAR.